Most guidelines recommend angiotensin-converting enzyme (ACE) inhibitors as first-line therapy for patients with cardiovascular disease,
but
Investigators conducted a review of 119 randomized clinical trials of ACE inhibitors and angiotensin II receptor blockers (ARBs) in more than half a million patients.
They found that ARBs were just as effective as ACE inhibitors when it came to improving blood pressure, slowing nephropathy, and reducing complications in heart failure.
ARBs are also associated with fewer adverse effects, including cough and angioedema. About 20% of patients on ACE inhibitors report cough, while ARBs have a minimal cough incidence.
One benefit of ACE inhibitors is that they are cheaper, but both are available now as generics.
اخبار النادي الأهلي المصري اضغط هنا
معلومات طبية و دليل الأدوية اضغط هنا